Tretinoin (all-trans retinoic acid)

Tretinoin is the gold-standard topical retinoid since 1971, with A-tier evidence for acne (any concentration) and photoaging (Kligman trials, multiple RCTs at 0.025-0.1%). It works via RAR activation → keratinocyte differentiation, comedolysis, and dermal collagen synthesis. For Dylan: SKIP for current nose perioral dermatitis — tretinoin is a documented trigger and aggravator of POD; the standard-of-care for POD is "zero-therapy" (stop all topicals) plus oral tetracycline if needed, NOT add a retinoid. Once POD resolves, tretinoin becomes an OPTIONAL-ADD for long-term acne control + photoaging prevention; until then it's the wrong tool for his active symptom.

Tretinoin is all-trans retinoic acid (ATRA) — the endogenous, biologically active metabolite of retinol (vitamin A). When applied topically, it diffuses through the stratum corneum and binds nuclear retinoic acid receptors (RARs) in skin cells. RARs are ligand-activated transcription factors with three isoforms:

• RAR-α — broadly expressed
• RAR-β — modulated in differentiation
• RAR-γ — the predominant isoform in epidermis (~90% of epidermal RAR), the main mechanism for tretinoin's keratinocyte effects

Tretinoin is a pan-RAR agonist (binds all three). In contrast, adapalene (Differin) is selective for RAR-β/γ — gentler because it skips RAR-α-mediated inflammation pathways.

Mechanistic layers:

1. Keratinocyte differentiation + comedolysis (anti-acne). Tretinoin normalizes the abnormal follicular keratinization that produces microcomedones (the precursor to all acne lesions). It induces orderly desquamation, prevents corneocyte cohesion in the follicle, and clears existing plugs. Onset: visible reduction in comedones at 4-8 weeks; full effect 12-16 weeks. This is the FDA-approved mechanism for acne (1971).

2. Sebocyte modulation. Reduces sebaceous gland activity and sebum production (mechanism less direct than oral isotretinoin, which apoptoses sebocytes; tretinoin modulates rather than ablates).

3. Dermal collagen synthesis (anti-photoaging). Activates fibroblast RARs → upregulates procollagen I and III transcription. Simultaneously suppresses AP-1/MMP-1 (the matrix metalloproteinase that UV induces and that breaks down dermal collagen). Net effect over 6-12 months: measurable increase in dermal collagen density, reduction in fine wrinkles, normalization of dyspigmentation. This is the FDA-approved mechanism for Renova (1995, photodamage).

4. Epidermal turnover acceleration. Increases mitotic rate of basal keratinocytes → faster epidermal renewal. Visible effects: smoother texture, brighter tone (clearance of stratum corneum dyschromia), gradual lightening of post-inflammatory hyperpigmentation.

5. Pigmentation effects. Inhibits tyrosinase indirectly + accelerates melanin clearance via epidermal turnover. Adjunct in melasma (typically combined with hydroquinone + a corticosteroid in Kligman's formula / triple-combination cream).

6. Pro-inflammatory cascade — the source of the irritation profile AND the POD problem. Tretinoin transiently induces low-grade inflammation in the first 4-8 weeks: erythema, scaling, peeling (the "retinization" or "retinoid uglies" phase). For most users this resolves with tolerance. For users with rosacea, perioral dermatitis, seborrheic dermatitis, or barrier-compromised skin, this inflammation can precipitate or worsen the underlying condition. Tretinoin is on every dermatology textbook's short list of topical agents that trigger or aggravate periorificial dermatitis.

Plain English: Tretinoin tells skin cells to act young — turn over faster, build collagen, clear plugs, normalize differentiation. It's the most replicated topical anti-aging intervention in dermatology. The catch is that the "telling them to act young" comes with a 4-8 week irritation window, and for already-inflamed skin (rosacea, POD, eczema), it can pour gas on the fire.